The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Study of the Potential Association of Adipose Tissue GLP-1 Receptor with Obesity and Insulin Resistance
Open accessAbstract
The increase in glucagon-like peptide-1 (GLP-1) activity has emerged as a useful therapeutic tool for the treatment of type 2 diabetes mellitus. The actions of GLP-1 on β-cells and the nervous and digestive systems are well known. The action of this peptide in adipose tissue (AT), however, is still poorly defined. Furthermore, no relationship has been established between GLP-1 receptor (GLP-1R) in AT and obesity and insulin resistance (IR). We provide evidence for the presence of this receptor in AT and show that its mRNA and protein expressions are increased in visceral adipose depots from morbidly obese patients with a high degree of IR. Experiments with the 3T3-L1 cell line showed the lipolytic and lipogenic dose-dependent effect of GLP-1. Moreover, GLP-1 stimulated lipolysis in 3T3-L1 adipocytes in a receptor-dependent manner involving downstream adenylate cyclase/cAMP signaling. Our data also demonstrate that the expression of the GLP-1R in AT correlated positively with the homeostasis model assessment index in obese IR subjects. Furthermore, prospective studies carried out with patients that underwent biliopancreatic diversion surgery showed that subjects with high levels of GLP-1R expression in AT, which indicates a deficit of GLP-1 in this tissue, were those whose insulin sensitivity improved after surgery, suggesting the potential relationship between AT GLP-1R and insulin sensitivity amelioration in obese subjects. Altogether these results indicate that the GLP-1/GLP-1R system in AT represents another potential candidate for improving insulin sensitivity in obese patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Accordingly, numerous studies have shown that following glucose overload, IR and diabetes clearly exhibit a decrease in circulating GLP-1 [58,67].”
From Adipose Tissue: A Novel Target of the Incretin Axis? A Paradigm Shift in Obesity-Linked Insulin Resistance (2024) · cites this paper as [58]
The cited source says what the claim attributes to it.
In the citing paper
“On the contrary, the functional classification of OB individuals based on the degree of IR revealed that, in the context of a very high degree of IR, GLP-1R in VAT depots was significantly up-regulated.”
From Adipose Tissue: A Novel Target of the Incretin Axis? A Paradigm Shift in Obesity-Linked Insulin Resistance (2024) · cites this paper as [58]
The cited source says what the claim attributes to it.
In the citing paper
“It is interesting that these authors showed that mature adipocytes and stromal vascular fraction (SVF), which include mesenchymal stem cells (MSCs), preadipocytes, fibroblasts, vascular endothelial cells and a variety of immune cells like AT macrophages, expressed GLP-1R at both the mRNA and protein levels.”
From Adipose Tissue: A Novel Target of the Incretin Axis? A Paradigm Shift in Obesity-Linked Insulin Resistance (2024) · cites this paper as [58]
The cited source says what the claim attributes to it.
In the citing paper
“Since the 1990s, reports have indicated that isolated mouse and human adipocytes contain GLP1-R ([58], and references therein).”
From Adipose Tissue: A Novel Target of the Incretin Axis? A Paradigm Shift in Obesity-Linked Insulin Resistance (2024) · cites this paper as [58]
In the citing paper
“Vendrell et al. [58] firstly reported that GLP-1R in human AT is likely correlated with the degree of IR and that there is a definite up-regulation of GLP-1R at the gene and protein levels in the visceral fat depot in individuals with morbid obesity (OB) and a high degree of IR.”
From Adipose Tissue: A Novel Target of the Incretin Axis? A Paradigm Shift in Obesity-Linked Insulin Resistance (2024) · cites this paper as [58]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mechanisms linking obesity to insulin resistance and type 2 diabetes
Kahn, S. E., Hull, R. L., & Utzschneider, K. M. (2006) · Nature · doi:10.1038/nature05482 · Cited by 5,448
Abdominal obesity and metabolic syndrome
Després, J.-P., & Lemieux, I. (2006) · Nature · doi:10.1038/nature05488 · Cited by 4,354
The biology of incretin hormones
Drucker, D. J. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.01.004 · Cited by 2,210
Islet cell failure in type 2 diabetes
Prentki, M. (2006) · Journal of Clinical Investigation · doi:10.1172/jci29103 · Cited by 1,690
Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.
Flint, A., Raben, A., Astrup, A., & Holst, J. J. (1998) · Journal of Clinical Investigation · doi:10.1172/jci990 · Cited by 1,402
Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients
Toft-Nielsen, M.-B., Damholt, M. B., Madsbad, S., Hilsted, L. M., Hughes, T. E., Michelsen, B. K., & Holst, J. J. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.8.7750 · Cited by 869
Weyer, C., Foley, J. E., Bogardus, C., Tataranni, P. A., & Pratley, R. E. (2000) · Diabetologia · doi:10.1007/s001250051560 · Cited by 799
Weight Change and Diabetes Incidence: Findings from a National Cohort of US Adults
Ford, E. S., Williamson, D. F., & Liu, S. (1997) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a009256 · Cited by 624
Gutzwiller, J.-P., Drewe, J., Göke, B., Schmidt, H., Rohrer, B., Lareida, J., & Beglinger, C. (1999) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.1999.276.5.r1541 · Cited by 521
Nielsen, L. L., Young, A. A., & Parkes, D. G. (2004) · Regulatory Peptides · doi:10.1016/j.regpep.2003.10.028 · Cited by 457
Cited by
Glucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868
“These recent studies include the finding of the receptor in differentiating mouse 3T3-L1 pre-adipocytes [382e384], adipocytes formed from human bone marrow-derived mesenchymal stem cells [385], human epicardial fat [386], and in human visceral white adipose tissue [387].”
BackgroundPharmacology, physiology, and mechanisms of incretin hormone action.
Campbell, J. E., & Drucker, D. J. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.04.008 · Cited by 1,500
“GLP-1 (10–100 nM, 4 hr) increased lipolytic rates in human primary adipocytes in vitro (Vendrell et al., 2011).”
BackgroundTrends in insulin resistance: insights into mechanisms and therapeutic strategy
Li, M., Chi, X., Wang, Y., Setrerrahmane, S., Xie, W., & Xu, H. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01073-0 · Cited by 939
“For example, (1) Glucagon-like peptide 1 (GLP1) is an intestinal hormone that can enhance insulin secretion in a glucosedependent manner by activating the GLP-1 receptor (GLP-1R) that is highly expressed on islet β cells.(462,463) GLP-1 receptor agonists including Liraglutide, Semaglutide, Dulaglutide and Exenatide ha…”
BackgroundGlucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis
Armstrong, M. J., Hull, D., Guo, K., Barton, D., Hazlehurst, J. M., Gathercole, L. L., Nasiri, M., Yu, J., Gough, S. C., Newsome, P. N., et al. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.08.038 · Cited by 456
“Interestingly, Vendell and colleagues reported that GLP-1R expression (mRNA, protein) is greatest in adipocytes isolated from patients with morbid obesity and in particular, IR [35].”
BackgroundRegulation of adipocyte lipolysis
Frühbeck, G., Méndez-Giménez, L., Fernández-Formoso, J.-A., Fernández, S., & Rodríguez, A. (2014) · Nutrition Research Reviews · doi:10.1017/s095442241400002x · Cited by 429
“A dose-dependent lipolytic effect of GLP-1 in 3T3-L1 adipocytes in a receptor-dependent manner involving downstream adenylate cyclase/cAMP signalling has been shown((83)).”
Metadata
- Authors
- Vendrell, J., El Bekay, R., Peral, B., García-Fuentes, E., Megia, A., Macias-Gonzalez, M., Real, J. F., Jimenez-Gomez, Y., Escoté, X., Pachón, G., Simó, R., Selva, D. M., Malagón, M. M., & Tinahones, F. J.
- Affiliations
- Instituto de Salud Carlos III (ES)
- University Hospital of Tarragona Joan XXIII (J.V., A.M., X.E., G.P.), IISPV, Rovira i Virgili University, Centro de Investigación Biomédica en Red Diabetes y Enfermedades Metabólicas Asociadas, Instituto de Salud Carlos III, 43007 Tarragona, Spain
- Consejo Superior de Investigaciones Científicas (ES)
- Laboratorio de Investigación Biomédica (R.E.B., E.G.-F., M.G., Y.J.-G., F.J.T.), Hospital Virgen de la Victoria, 29010 Málaga, Spain
- Department of Cell Biology, Physiology, and Immunology (Y.J.-G., M.M.M.), Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y Nutrición (CB06/03/0020) and Instituto de Salud Carlos III, Instituto de Investigación Biomédica, University of Córdoba, 14004 Córdoba, Spain
- Centro de Investigación Biomédica en Red Diabetes y Enfermedades Metabólicas Asociadas (ES)
- Venue
- Endocrinology
- Publisher
- The Endocrine Society
- Published
- 2011-08-23
- Volume
- 152
- Issue
- 11
- Pages
- 4072-4079
- ISSN
- 0013-7227 (ISSN-L)
- 1945-7170
- OpenAlex
- W2143149722
- Cited by
- 173
- References
- 28
- Citations by year
- 2026: 13 · 2025: 18 · 2024: 16 · 2023: 16 · 2022: 11 · 2021: 11 · 2020: 12 · 2019: 10 · 2018: 7 · 2017: 8 · 2016: 12 · 2015: 11 · 2014: 12 · 2013: 11 · 2012: 5
- FWCI
- 6.72
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Endocrinology (publishedVersion)
- PubMed (publishedVersion)
- DIGITAL.CSIC (Spanish National Research Council (CSIC)) (submittedVersion, other-oa)
- Funders
- Ministerio de Ciencia e Innovación (SAF-2009-10461)
- Servicio Andaluz de Salud
- Instituto de Salud Carlos III (PS09/00997, PI070953)
- European Regional Development Fund
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Physiology (medical) › Adipose Tissue and Metabolism
- Keywords
- GLP-1 receptor, adipose tissue, obesity, insulin resistance, lipolysis, lipogenesis, 3T3-L1 adipocytes, biliopancreatic diversion, insulin sensitivity, visceral adipose tissue, type 2 diabetes
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Adipose Tissue, Animals, Cells, Cultured, Humans, Insulin Resistance, Obesity, Morbid, Prospective Studies, Adipocytes, Receptors, Glucagon, 3T3-L1 Cells, Mice, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Study of the Potential Association of Adipose Tissue GLP-1 Receptor with Obesity and Insulin Resistance. https://app.cochat.ai/papers/10.1210/en.2011-1070
- The paper
- Vendrell, J., El Bekay, R., Peral, B., García-Fuentes, E., Megia, A., Macias-Gonzalez, M., Real, J. F., Jimenez-Gomez, Y., Escoté, X., Pachón, G., Simó, R., Selva, D. M., Malagón, M. M., & Tinahones, F. J. (2011). Study of the Potential Association of Adipose Tissue GLP-1 Receptor with Obesity and Insulin Resistance. Endocrinology. https://doi.org/10.1210/en.2011-1070
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.